Rationale: People with CF treated with IV antibiotics for a pulmonary exacerbation (PEx) frequently fail to recover to baseline FEV 1 . The long-term impact of these events has not been studied. We randomly selected one PEx per patient that met inclusion/exclusion criteria.
studies have demonstrated that recovery to spirometric baseline does not occur for a substantial proportion of patients following treatment with IV antibiotics for a PEx. [6] [7] [8] [9] [10] This change in baseline lung function may be associated with further adverse outcomes, as patients with lower lung function have higher rates of PEx treatments, lower quality of life, and increased risk of death. 2, 11, 12 A previous analysis found that 58% of patients who initially had poor spirometric recovery, defined as the best forced expiratory volume in 1 s (FEV 1 ) % predicted in the 3 months after a PEx that was less than 90% of the best FEV 1 % predicted in the 6 months before the PEx, did not recover to the pre-exacerbation baseline in the 12 months after the PEx. 7 In addition, patients treated with one or more courses of IV antibiotics for a PEx are at-risk for a shorter time to the next PEx, 13 although it is unknown if the lack of spirometric recovery after a PEx is associated with further shortening of the time to the next PEx.
Understanding this relationship is important in identifying patients most at-risk for future PEx treatments and their associated adverse outcomes.
We hypothesized that poor spirometric recovery after a PEx treated with IV antibiotics would be associated with a shorter time to the next PEx. We also tested whether patients with poor spirometric recovery at the initial PEx were at increased risk for poor recovery at the next recorded PEx and/or more treatments with IV antibiotics over the subsequent 3 years. We evaluated our hypothesis using data from the national CF Foundation Patient Registry (CFFPR). 14 Some of the results of these studies have been previously reported in the form of an abstract. 15 
| MATERIALS AND METHODS
We included data from individuals enrolled in the CFFPR from were excluded if they were for reasons other than a PEx. PEx episodes were excluded if there was less than 12 months of data in the CFFPR before and after the PEx, or if there were no measurements of FEV 1 recorded within the 6 months before and/or 3 months after the PEx.
We excluded any PEx with a recorded treatment duration of <2 days, although our conclusions were not affected if we excluded PEx episodes of less than 3, 4, or 5 days. Patients were defined as Non-
Responders if their best FEV 1 measurement (in liters) in the 3 months after the PEx was <90% of the best FEV 1 measurement (in liters) in the 6 months before the PEx. FEV 1 is reported as percent predicted values, calculated using Global Lung Initiative equations. 17 We excluded any PEx from our analysis if another PEx occurred prior to the best FEV 1 in the 3 months following the analyzed PEx.
| Statistical analyses
Descriptive statistics were used to summarize patient characteristics. predicted, and have CF-related diabetes (Table 1) Table S1 ). The proportion of female patients was higher among pediatric Non-Responders, but not adult NonResponders.
In As reported previously, 18 the number of exacerbations treated with IV antibiotics in the previous 12 months had the strongest association with a shorter time to the next PEx ( Table S2 ).
We then repeated our analyses, defining Non-Responders as SANDERS ET AL. has been stable for at least the past 20 years. 14 Waters et al. showed that a substantial proportion of overall FEV 1 decline is attributable to exacerbations. 19 Vandevanter et al. 18 showed that having one course of IV antibiotics to treat a PEx is a very strong predictor of having another course of IV antibiotics, an effect also seen in our analysis.
Although our analysis shows that poor PEx recovery is associated with a shorter time to the next PEx, it should be noted that the PEx history had a much stronger effect.
Each of these studies, including our report, is observational and cannot prove causality. Furthermore, there is limited data to support specific PEx treatments that can improve PEx recovery or longer-term poor outcomes. A recent study did demonstrate that adult patients treated with 7% hypertonic saline during a PEx were more likely to recover to baseline FEV 1 than patients who received a saline placebo. 20 An analysis of an observational study of adolescents and adults with CF treated with IV antibiotics for a PEx did not identify any best practices associated with improved outcomes. 10 In Having poor recovery at the initial PEx was associated with a significantly increased risk of poor recovery after the second PEx. In our analysis, patients who were in the Non-Responder group for both PEx episodes experienced a >15% decrease in mean FEV 1 % predicted from before the initial PEx to after the second, over a time period that could be less than 2 years (Fig. 3) . Given the time between events, it is unlikely that the poor response at the initial PEx directly caused the poor recovery at the second PEx. It is possible that poor recovery may be a specific PEx phenotype that may be affected by characteristics of the patient, lung disease phenotype, 21 PEx etiology (eg, viral infections, FIGURE 2 Kaplan-Meier time-to-PEx according to degree of spirometric recovery at a randomly selected PEx. According to our inclusion criteria, data was available for all patients for the first 12 months after the chosen PEx The large size of the CFFPR is a strength that allowed us to find associations between poor PEx recovery and long-term outcomes, but the observational nature of this study has limitations. First, it is possible that the association between poor PEx recovery and time to the next PEx is due to indication bias, that is, clinicians recognize that patients did not respond as expected after the first treatment, so they choose to treat with IV antibiotics again. However, the median time between consecutive PEx treatments was over 7 months, so it is unlikely that clinicians treated these as linked events. Additionally, in surveys, the majority of treating physicians view PEx treatment as a success, even when FEV 1 has not returned to previous baseline values. 22 smoke exposure occurs most often in families with low socioeconomic status, and has independent effects on pulmonary outcomes. A recent report indicated that children exposed to tobacco smoke were more likely to have crackles and wheezes on exam. 30 While disparities in CF lung disease related to socioeconomic status have not been explained by differential treatment of pulmonary exacerbations, 27 the presence of these respiratory findings are associated with increased frequency of antibiotic courses. 31 Tobacco smoke exposure is likely underreported in the CFFPR, and so we did not evaluate it in our models.
Finally, it should be acknowledged that recovering to within 90% of the previous baseline FEV 1 is less than an ideal goal of therapy. This level of recovery was chosen to allow for the inherent variability in FEV 1 measurements, 32, 33 as well as the possibility that patients' true best FEV 1 may occur when they are not in clinic, and therefore, not measured. The magnitude and statistical significance of our conclusions were not affected when we changed the definition of recovery to recovering to 100% of the previous baseline. It should be noted that 48.6% of patients failed to achieve this goal.
In conclusion, we have described an association between poor spirometric recovery from a PEx and a shorter time to the next PEx. As described previously, having recent exacerbation(s) treated with IV 
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